Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease worldwide, ranging from simple steatosis to nonalcoholic steatohepatitis, which may progress to cirrhosis, eventually leading to hepatocellular carcinoma (HCC). HCC ranks as the third highest cause of cancer-related death globally, requiring an early diagnosis of NAFLD as a potential risk factor. However, the molecular mechanisms underlying NAFLD are still under investigation. So far, many in vitro studies on NAFLD have been hampered by the limitations of 2D culture systems, in which cells rapidly lose tissue-specific functions. The present liver-on-a-chip approach aims at filling the gap between conventional in vitro models, often scarcely predictive of in vivo conditions, and animal models, potentially biased by their xenogeneic nature. METHODS: HepG2 cells were cultured into a microfluidically perfused device under free fatty acid (FFA) supplementation, namely palmitic and oleic acid, for 24h and 48h. The device mimicked the endothelial-parenchymal interface of a liver sinusoid, allowing the diffusion of nutrients and removal of waste products similar to the hepatic microvasculature. Assessment of intracellular lipid accumulation, cell viability/cytotoxicity and oxidative stress due to the FFA overload, was performed by high-content analysis methodologies using fluorescence-based functional probes. RESULTS: The chip enables gradual and lower intracellular lipid accumulation, higher hepatic cell viability and minimal oxidative stress in microfluidic dynamic vs. 2D static cultures, thus mimicking the chronic condition of steatosis observed in vivo more closely. CONCLUSIONS: Overall, the liver-on-a-chip system provides a suitable culture microenvironment, representing a more reliable model compared to 2D cultures for investigating NAFLD pathogenesis. Hence, our system is amongst the first in vitro models of human NAFLD developed within a microfluidic device in a sinusoid-like fashion, endowing a more permissive tissue-like microenvironment for long-term culture of hepatic cells than conventional 2D static cultures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727 · cited 1×
“Hence, the development of three dimensional (3D) models with increased spatial and chemical complexity is being pursued, in order to better recreate cell-cell interactions within their own microenvironment [1,2].”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Kim, H. J., Li, H., Collins, J. J., & Ingber, D. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522193112 · Cited by 922
A Human Hepatocellular in Vitro Model to Investigate Steatosis
Gómez-Lechón, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V., & O’Connor, J.-E. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.004 · Cited by 576
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476
Organ-on-a-chip platforms for studying drug delivery systems
Bhise, N. S., Ribas, J., Manoharan, V., Zhang, Y. S., Polini, A., Massa, S., Dokmeci, M. R., & Khademhosseini, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.004 · Cited by 381
Biomimetic tissues on a chip for drug discovery
Ghaemmaghami, A. M., Hancock, M. J., Harrington, H., Kaji, H., & Khademhosseini, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.029 · Cited by 359 · cited 1×
“To date, however, the study of chronic pathophysiological states in clinically relevant models and time scales, remains the main challenge [5].”
BackgroundZhang, C., Zhao, Z., Abdul Rahim, N. A., van Noort, D., & Yu, H. (2009) · Lab on a Chip · doi:10.1039/b915147h · Cited by 340 · cited 1×
“Current research in the field aims to reproduce living systems on a chip [7,8] without the presumption to totally replace animal testing, but certainly to reduce it and provide novel and more reliable disease models [9].”
BackgroundYoon No, D., Lee, K.-H., Lee, J., & Lee, S.-H. (2015) · Lab on a Chip · doi:10.1039/c5lc00611b · Cited by 205
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow
Esch, M. B., Prot, J.-M., Wang, Y. I., Miller, P., Llamas-Vidales, J. R., Naughton, B. A., Applegate, D. R., & Shuler, M. L. (2015) · Lab on a Chip · doi:10.1039/c5lc00237k · Cited by 173
Cited by
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153
Liver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127
“Pathogenesis was characterized using intracellular triglyceride accumulation, cell viability, and cellular levels of reactive oxygen species (ROS).(22) FIg.”
BackgroundMethodIn Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
“have cultured HepG2 cells under free fatty acid (FFA) supplementation in a microfluidically perfused device, which mimics the endothelial–parenchymal interface of a liver sinusoid and allows the diffusion of nutrients and removal of waste products similar to that in liver microcirculation [67].”
BackgroundHuman in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118
Metadata
- Authors
- Gori, M., Simonelli, M. C., Giannitelli, S. M., Businaro, L., Trombetta, M., & Rainer, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-20
- Volume
- 11
- Issue
- 7
- Pages
- e0159729
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2501678433
- Cited by
- 176
- References
- 12
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.